In order to thoroughly implement the spirit of the Sixth Plenary Session of the Eighteenth Central Committee of the Party and the Party Central Committee、Decision and deployment of the State Council on the supervision of food and drug safety supervision，Accelerate the improvement of the quality and safety of drugs，Promoting the development of the pharmaceutical industry innovation drive，October 30，The Director of the Food and Drug Administration, Bi Jingquan, presided over a symposium，Listen to the opinions and suggestions of the reform and development of drug research and development of the drug review approval system。

 

  The person in charge of more than 10 pharmaceutical companies from China attended the discussion。Everyone Stake Sports Bettingagrees，The country's determination to reform the drug review approval system，It is a great thing for the benefit of the country and the people，For the construction of a modern drug supervision system，Improve the quality and competitiveness of Chinese manufacturing medicines，better meets the safety of public medication and effectiveness, which has important practical significance and far -reaching influence。The dividend of reform is gradually being released，Accelerate the approval of innovative drug reviews，The effect of helping and inferiority is being manifested，The innovative ecosystem of the pharmaceutical industry has improved significantly。Suggestion，We must persist in carrying the reform to the end，Further improve the review standard specifications and technical guidelines，Strengthen the construction of experts and technical teams，Provides more powerful guidance for the R & D and production of the enterprise，Create medicine that encourages innovation、Medical、Medical Insurance & LDQUO; Three Medical Links & RDQUO; Policy Environment。

 

  Bi Jingquan pointed out，The Party Central Committee with Comrade Xi Jinping as the core attaches great importance to food and drug safety work，The Sixth Plenary Session of the Eighteenth Central Committee of the Party's construction of the food and drug safety governance system、Reform of the Approval System of Drug Medical Devices Review and Approval、The reform of the drug circulation system has been further emphasized。Since the reform and opening up，Preliminary My stake betting appsolutions to the availability and sexual problems of Chinese medicine，Drug quality and regulatory level is gradually increasing，But there is still a gap with the expectations of the people。Current Drug R & D、Production、circulation、Questions in use，In essence, it is the supply side problem，It is a question that does not meet the growing demand of the people in the supply quality。The regulatory authorities must firmly establish the concept of the people -centered，Make sure the quality and efficacy of the marketing drugs。

 

  Bi Jingquan emphasizes，Strive to establish a drug review approval system that encourages innovation for innovation，Improve the regulations、Policy measures、Technical Guide，Clinical -oriented reconstructing the drug review process，Integrate regulatory resources with review as the center，Improve review ability and supervision efficiency，Research clinical trial management、Policy、Patent links, etc. closely related to innovation policies，Promote the transformation and upgrading and supply -side structural reform of the pharmaceutical industry with the regulatory system innovation。To change the concept of supervision，Regulatory supervision in service，Strengthen communication with the industry，Guide enterprises to implement quality and safety management specifications，Improve product quality and international competitiveness。To quickly promote the consistency evaluation of the quality of the quality of generic drugs，Achievement of generic drugs and original research drugs in clinical replacement。stake betting appDo a good job of the holder system of the drug listing permit、Craft verification and other work，Summary experience，Policy。

 

  Bi Jingquan highly affirmed the important role played by enterprises in the reform of the drug review and approval system。He pointed out，To further enhance the confidence in developing innovative industries。Pharmaceutical companies are bigger and stronger，It is conducive to promoting the pharmaceutical industry from relying on quantity expansion to focusing on quality and efficiency transformation，It is conducive to promoting the well -being of the general public。Enterprise is the main body to ensure the quality and safety of drugs，is the main force of technological innovation，It is also an important force to promote the reform and innovation of the regulatory system。Hope that pharmaceutical companies actively participate in the reform of the review and approval system，Give full play to its own advantages，Actively build suggestions，Work with the regulatory authorities to improve the relevant system specifications。Strictly follow the various regulations and systems of drug production and operation，Improve quality and safety guarantee ability，Ensure that the safety of listed drugs is effective and effective。

 

  Cornerstone biopharmaceuticals、Qilu Pharmaceutical、Task Pharmaceutical、Boskin Biopharmaceutical、Treasure Island Pharmaceutical、Kang Zhe Pharmaceutical、Corning Jerer Biopharmaceutical、Beijing Kayin Biopharmaceutical、Xianyin Pharmaceutical、Rongchang Pharmaceutical、stake online sports bettingShenwei Pharmaceutical、The person in charge of Shenghe Pharmaceutical and experts from Shenyang Pharmaceutical University attended the discussion。

 

  Deputy Director of the General Administration、Deputy Director Sun Xianze, and the main responsible comrades of the relevant departments and direct units attended the symposium。